MedPage Today September 17, 2025
Telehealth companies promoting unofficial drugs targeted for the first time
For the first time, federal health officials are taking aim at telehealth companies promoting unofficial versions of prescription drugs — including popular weight-loss medications — as part of the Trump administration’s crackdown on pharmaceutical advertising.
The FDA on Tuesday posted more than 100 letters to various drugmakers and online prescribing companies, including Hims & Hers, which has built a multibillion-dollar business centered around lower-cost compounded versions of blockbuster obesity injections.
The FDA warned the company to remove “false and misleading” promotional statements from its website, including language claiming that its customized products contain “the same active ingredient” as FDA-approved semaglutide (Ozempic, Wegovy). The formulations cited by regulators are produced by...
Today's Sponsors
Today's Sponsor